Board Of Directors

Indivior’s Board of Directors offers global pharmaceutical and biotechnology executive management experience, including expertise in corporate governance, science and policy, medicines development, audit, risk and financial management. The Board is collectively responsible for the long-term success of the Company and for delivering value to shareholders.

Graham Hetherington

Chair

Mark Crossley

Chief Executive Officer

Ryan Preblick

Chief Financial Officer

Peter Bains

Independent Non-Executive Director

A. Thomas McLellan Ph.D

Independent Non-Executive Director

Lorna Parker

Independent Non-Executive Director

Daniel J. Phelan

Independent Non-Executive Director

Kathryn Hudson

Company Secretary

Jerome Lande

Non-Executive Director

Joanna Le Couilliard

Independent Non-Executive Director

Juliet Thompson

Independent Non-Executive Director

Mark Stejbach

Independent Non-Executive Director

Executive Committee

Indivior’s Executive Committee has significant experience in addiction medicine and mental health diseases focused on identifying unmet patient needs, medicines development and global product commercialization. Indivior’s leadership has established a clearly-defined set of principles and behaviors to enable a patient-focused culture that strives for the highest standards of business, financial and ethical performance at all times.

Mark Crossley

Chief Executive Officer

Ryan Preblick

Chief Financial Officer

Cynthia (Cindy) Cetani

Chief Integrity and Compliance Officer

Jon Fogle

Chief Human Resources Officer

Christian Heidbreder

Chief Scientific Officer

Richard Simkin

Chief Commercial and Strategy Officer

Hillel West

Chief Manufacturing and Supply Officer

Kathryn Hudson

Company Secretary